(MENAFN- GlobeNewsWire - Nasdaq) Clinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), Immune Thrombocytopenia (ITP), and Systemic Lupus Erythematosus (SLE) on Track to Initiate ...

Climb Bio plans to evaluate budoprutug in multiple clinical trials across three lead indications-primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus ...

Pursuing ex-U.S. regulatory clearance for budoprutug clinical trial in SLE. Following the Company ... membranous nephropathy (pMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus ...

Clinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), Immune Thrombocytopenia (ITP), and Systemic Lupus Erythematosus (SLE) on Track to Initiate in 2025 CLYM116 Progressing Towards ...

In conclusion, through formal Delphi methodology, consensus was achieved to include eight domains of active SLE (alopecia, arthritis, haemolytic anaemia, nephritis, mucosal ulcers, rash, serositis and ...

Results Baseline protein expression differed between patients with SLE and healthy donors ... neutropenia, monocytopenia and thrombocytopenia, including alterations in hematopoiesis, changes in ...

The Scottish Government’s newly unveiled Programme for Government includes several promising commitments for rural communities, though Scottish Land & Estates (SLE) has called for a more consistent ...

Super League Enterprise, Inc. creates and publishes content experiences and media solutions across immersive platforms in the United States and internationally. Its proprietary cloud-based ...

Pursuing ex-U.S. regulatory clearance for budoprutug clinical trial in SLE. Following the Company’s receipt of clearance from the FDA of its IND for SLE, the Company is also pursuing regulatory ...

SANTA MONICA, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- Super League Enterprise, Inc. (NASDAQ: SLE) (the “Company”), a leader in redefining how brands connect with consumers through the power ...